Spectrum Pharma acquires 100% rights to RenaZorb from Altair Nanotechnologies

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology, announced that it has acquired 100 per cent rights to RenaZorb (a family of compounds represented by SPI-014, also known as RZB-014), from Altair Nanotechnologies. RenaZorb is a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications.

Comments

Post a Comment

Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Image
GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut    Vox Author of GOP Tax Plan Says Children's Health Insurance Program Is Held Up “Because We Don't Have Money ...    The Intercept Nevada wins short reprieve in child health care funds fight    Sacramento Bee Ben McAdams: Congress to Tiny Tim: 'No health insurance for you.'    Salt Lake Tribune Full coverage
Read more

Trump wants more mental health care; Alabama says it's trying

Image
Trump wants more mental health care; Alabama says it's trying    AL.com Budget undercuts Trump focus on mental health, school safety    Yahoo News Mental health awareness license plates offered by New York State DMV    Buffalo News Trump wants to 'tackle the difficult issue of mental health?' He should put his money where his mouth is.    Washington Post Full coverage
Read more